T2 Biosystems Raises $10.8M in Private Financing, Inks In-Q-Tel Pact | GenomeWeb
NEW YORK (GenomeWeb News) – T2 Biosystems has raised $10.8 million in a Series B financing, the Cambridge, Mass.-based firm said today.
 
T2 will use proceeds from the financing to accelerate development of its portable diagnostics system that combines nanotechnology with miniaturized magnetic resonance technology. The firm said that the technology has been validated for accurately analyzing viruses, bacteria, proteins, hormones, DNA, small molecules, and other diagnostic targets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.